TSE:4523Pharmaceuticals
Does Strong Lecanemab Treatment Persistence Reshape The Bull Case For Eisai (TSE:4523)?
Eisai and its partners recently reported real-world data at the AD/PD 2026 conference showing that most early Alzheimer’s patients in the U.S. remained on intravenous lecanemab beyond 18 months, with persistence still above two-thirds at 24 months, broadly aligning with outcomes seen in the Phase 3 Clarity AD trial and its long-term extension.
The new findings, alongside expanding approvals and filings for more convenient maintenance and subcutaneous lecanemab dosing, reinforce the therapy’s...